FDA
-
-
-
-
-
-
-
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
-
-
-
-
-
-
-
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
-
-
-
-
-
-
-
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
-
-
-
-
-
-
-
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
-
-
-
-
-
-
-
Moleculin launches CEO Corner platform for investor communication
-
-
-
-
-
-
-
Moleculin reports positive Phase 1 results for pediatric brain tumor drug
-
-
-
-
-
-
-
Moleculin Announces New Annamycin Collaboration in Brain Tumors
-
322,950 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

